1981
High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer.
Jones R, Collins J, Myers C, Brooks A, Hubbard S, Balow J, Brennan M, Dedrick R, DeVita V. High-volume intraperitoneal chemotherapy with methotrexate in patients with cancer. Cancer Research 1981, 41: 55-9. PMID: 7448776.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaDialysisFemaleHumansInjections, IntraperitonealMelanomaMethotrexateOvarian NeoplasmsConceptsEpisodes of bacterial peritonitisNovel treatment modalitiesTotal body clearanceIntraperitoneal chemotherapyPeritoneal irritationChemotherapeutic regimensMethotrexate clearanceBacterial peritonitisOvarian cancerMalignant melanomaTreatment modalitiesLocal toxicitySystemic toxicityPlasma levelsPeritoneal cavitySystemic circulationTreatment cyclesPlasma concentrationsMethotrexate concentrationsTherapeutic benefitBody clearancePatientsMethotrexateChemotherapyPeritonitis
1980
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally.
Speyer J, Collins J, Dedrick R, Brennan M, Buckpitt A, Londer H, DeVita V, Myers C. Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Research 1980, 40: 567-72. PMID: 7471076.Peer-Reviewed Original ResearchMeSH KeywordsColonic NeoplasmsDrug Administration ScheduleDrug EvaluationFemaleFluorouracilHumansInjections, IntraperitonealOvarian NeoplasmsConceptsPeritoneal fluid concentrationsPlasma levelsGram-negative bacterial peritonitisTenckhoff peritoneal dialysis catheterCentral nervous system toxicityStudy of 5-fluorouracilDose-limiting toxicityPeritoneal fluid levelsSimultaneously measured plasma levelsPhase I studyPeritoneal dialysis catheterNervous system toxicityMild abdominal discomfortRoute of administrationTotal body clearanceFluid concentrationsPattern of toxicityBacterial peritonitisDialysis catheterAbdominal discomfortSystemic toxicityPharmacological advantagesDialysate concentrationsBody clearanceFluid levels
1978
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer.
Dedrick R, Myers C, Bungay P, DeVita V. Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Journal Of The National Cancer Institute 1978, 62: 1-11. PMID: 626987.Peer-Reviewed Original ResearchMeSH KeywordsAntineoplastic AgentsAscitic FluidCytarabineFemaleHumansInjections, IntraperitonealMethotrexateModels, BiologicalOvarian NeoplasmsTissue DistributionConceptsOvarian cancerResidual ovarian cancerTreatment of patientsPharmacokinetic rationalePlasma clearancePeritoneal cavityPeritoneal spaceDrug AdministrationPharmacokinetic calculationsPeritoneal permeabilitySuch drugsCancerAnticancer drugsDrugsTreatmentHydrophilic anticancer drugPatientsAdministrationClearance
1970
Pentamidine: Clinical pharmacologic correlations in man and mice
Waalkes T, Denham C, DeVita V. Pentamidine: Clinical pharmacologic correlations in man and mice. Clinical Pharmacology & Therapeutics 1970, 11: 505-512. PMID: 5310706, DOI: 10.1002/cpt1970114505.Peer-Reviewed Original ResearchConceptsDiffuse interstitial pneumoniaInterstitial pneumoniaUrinary excretionPlasma levelsPneumocystis cariniiSingle intraperitoneal injectionTypes of pneumoniaDosage scheduleCancer patientsMalignant diseaseRenal abnormalitiesConcomitant useIntraperitoneal injectionIntramuscular administrationOrgan transplantationExcretion patternsPatientsPneumoniaPentamidineExcretionDrugsMenDiseaseMiceCarinii
1969
Plasma Pyridoxal Phosphate Depletion by the Carcinostatic Procarbazine
Chabner B, DeVita V, Considine N, Oliverio V. Plasma Pyridoxal Phosphate Depletion by the Carcinostatic Procarbazine. Experimental Biology And Medicine 1969, 132: 1119-1122. PMID: 5360989, DOI: 10.3181/00379727-132-34378.Peer-Reviewed Original ResearchAnimalsAntineoplastic AgentsBenzoatesHydrazinesInjections, IntraperitonealMaleMicePyridoxal Phosphate